ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Oct 29, 2026
Funding
ARTHEx Biotech Secures $87M to Advance RNA Medicines
Sep 17, 2025
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million to advance its lead program ATX-01 for Myotonic Dystrophy Type 1.
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million, announced in a press release. The funding was led by new investor Bpifrance, with participation from existing shareholders such as AdBio Partners and Columbus Venture Partners.
The proceeds will be used to further the global clinical development of ARTHEx's lead program, ATX-01, which targets Myotonic Dystrophy Type 1 (DM1). ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), a natural repressor of MBNL protein expression. This mechanism aims to increase MBNL production, decrease toxic DMPK mRNA, and improve splicing abnormalities in DM1 patients.
The financing will support the ongoing interventional Phase I/IIa ArthemiRTM study and prepare for an open-label extension to support a registrational study, further advancing ARTHEx's pipeline of targeted RNA medicines.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareMore from Funding
Nov 13 Polar DC adds Palistar financing as 2026 commitments pass EUR 1 billion Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 MISTT raises £5 million to build a space-and-time data layer for AI and autonomous systems Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 12 Inveniam acquires Docugami, the document AI startup of XML pioneer Jean PaoliFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Atlas Bio raises $12.5 million for virtual drug trials
Oct 27, 2026
Healthcare
Armatrix Raises ₹67.3 Crore in Seed Funding
Nov 03, 2026
Funding
Biomatter Raises $18 Million for AI Enzyme Design
Nov 12, 2026
Funding
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Funding
Araceli Biosciences Adds Investor to $4.5 Million Round
Nov 12, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.